Tesla owners grapple with brand loyalty as Elon Musk's political alignment with President Trump sparks controversy and ...

In a report released today, David Nierengarten from Wedbush maintained a Hold rating on Fate Therapeutics (FATE – Research Report), with a price target of $5.00. See what stocks are receiving ...

On February 28, Daniel Ives from Wedbush maintained a “Buy” rating on the stock with a price target of $22.00. SoundHound AI, offering innovative voice and conversational AI solutions across ...

Wedbush analyst S. Basham now forecasts that the company will post earnings per share of $0.48 for the year, down from their prior forecast of $0.58. Wedbush has a “Neutral” rating and a $10. ...

Wedbush also issued estimates for Geron’s Q3 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.14) EPS, FY2027 earnings at $0.43 EPS and FY2028 earnings at $0.84 EPS. Get Geron alerts: ...

The primary spending impact will be in the Banking, Financial Services and Insurance (BFSI) and High-Tech verticals, according to the note. According to Katri, there are no signs of a slowdown in ...

Wedbush analyst David Nierengarten maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $18. ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

Pro Bowl quarterback Joe Burrow has made it crystal clear how he wants the Cincinnati Bengals to approach this offseason. Do whatever it takes to ensure that wide receiver Ja'Marr Chase, edge ...

The market’s worries that Musk has too much on his plate isn’t swaying long-time bull Dan Ives of Wedbush, however. Ives wrote in a note Monday that he is sticking with his outperform rating ...